Aktuelle Standards in der Behandlung des Hodgkin Lymphoms

Johannes C. Hellmuth

doi:10.1055/a-2401-7792

Onkologische Welt, Table of Contents

Onkologische Welt 2024; 15(06): 348-356
DOI: 10.1055/a-2401-7792

Originalartikel

Aktuelle Standards in der Behandlung des Hodgkin Lymphoms

Johannes C. Hellmuth

¹Medizinische Klinik und Poliklinik III, LMU Klinikum, LMU München, München, Germany

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Hermann S, Kraywinkel K. Faktenblatt: Epidemiologie der Hodgkin-Lymphome in Deutschland. Onkologe 2018; 24: 280-285
2 Behringer K, Goergen H, Hitz F. et al Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. The Lancet 2015; 385: 1418-1427
3 Borchmann P, Plütschow A, Kobe C. et al PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 2021; 22: 223-234
4 Kreissl S, Goergen H, Buehnen I. et al PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 08: e398-e409
5 Leitlinienprogramm Onkologie. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten 2022; 205. 2022
6 Fuchs M, Goergen H, Kobe C. et al Positron Emission Tomography – Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology 2019
7 von Tresckow B, Plütschow A, Fuchs M. et al Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-913
8 Gillessen S, Plütschow A, Fuchs M. et al Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). The Lancet Haematology 2021; 08: e278-e288
9 Borchmann P, Moccia A, Greil R. et al Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial. Blood 2023; 142: 3057
10 Borchmann P, Moccia AA, Greil R. et al BrECADD Is Non-Inferior to eBEACOPP in Patients with Advanced Stage Classical Hodgkin Lymphoma: Efficacy Results of the GHSG Phase III HD21 Trial. Hematological Oncology 2023; 41: 881-882
11 Ansell SM, Radford J, Connors JM. et al Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine 2022; 387: 310-320
12 Connors JM, Jurczak W, Straus DJ. et al Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med 2018; 378: 331-344
13 Chen R, Gopal AK, Smith SE. et al Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562-1566
14 Armand P, Zinzani PL, Lee HJ. et al Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood 2023; 142: 878-886
15 Nogová L, Reineke T, Brillant C. et al Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434-439
16 Campo E, Jaffe ES, Cook JR. et al The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229-1253
17 Alaggio R, Amador C, Anagnostopoulos I. et al The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720-1748
18 Fanale MA, Cheah CY, Rich A. et al Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2017; 130: 472-477
19 Eichenauer DA, Engert A. How I treat nodular lymphocytepredominant Hodgkin lymphoma. Blood 2020; 136: 2987-2993
20 Bröckelmann PJ, Müller H, Guhl T. et al Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol 2021; 39: 107-115
21 Bröckelmann PJ, Müller H, Casasnovas O. et al Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Annals of Oncology 2017; 28: 1352-1358
22 Moskowitz AJ, Shah G, Schöder H. et al Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. JCO 2021; 39: 3109-3117
23 Moskowitz AJ, Shah G, Schöder H. et al T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma. HemaSphere 2022; 06: 45
24 Herrera AF, LeBlanc ML, Castellino SM. et al SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). JCO 2023; 41: LBA4-LBA4